Literature DB >> 9328474

Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens.

V Mak1, K A Jarvi, J Zielenski, P Durie, L C Tsui.   

Abstract

The 5-thymidine (5T) variant of the cystic fibrosis transmembrane conductance regulator (CFTR) intron 8 polypyrimidine tract (IVS8-T tract) is the most frequent CFTR gene alteration identified in men with congenital bilateral absence of vas deferens (CBAVD). This alternative splicing variant gives rise to two transcripts, one normal with exon 9 intact and the other with in-frame deletion of exon 9. That CBAVD men usually have none of the other clinical signs of classical cystic fibrosis (CF) suggests less functional CFTR is produced in the reproductive tract than in other CF-associated organs. Nasal epithelia and segments of vas deferens were obtained from healthy, previously vasectomized men who presented for vasectomy reversal. Quantitative RT-PCR was performed on these specimens, with the region of CFTR cDNA spanning exon 9 amplified. For both nasal and vasal tissues, a strong positive correlation was found between the length of the IVS8-T tract and the proportion of mRNA with exon 9 intact. In addition, within the same subject, a significantly higher level of transcripts lacking exon 9 was found in vas deferens than nasal epithelia, regardless of the IVS8-T genotype. These findings suggest that the splicing of CFTR precursor mRNA is less efficient in vasal epithelia compared with respiratory epithelia. Thus, differential splicing efficiency between the various tissues which express CFTR provides one possible explanation for the reproductive tract abnormalities observed in infertile men with CFTR gene alterations but without other clinical manifestations of CF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328474     DOI: 10.1093/hmg/6.12.2099

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

1.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

Review 2.  Genetics and pulmonary medicine. 1. The genetics of cystic fibrosis lung disease.

Authors:  D J Davidson; D J Porteous
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 3.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

4.  A rare frameshift variant in trans with the IVS9-5T allele of CFTR in a Chinese pedigree with congenital aplasia of vas deferens.

Authors:  Bin Ge; Mingzhe Zhang; Ruyi Wang; Dejing Wang; Tengyan Li; Hongjun Li; Binbin Wang
Journal:  J Assist Reprod Genet       Date:  2019-11-10       Impact factor: 3.412

5.  DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis.

Authors:  N Kälin; A Claass; M Sommer; E Puchelle; B Tümmler
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

6.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.

Authors:  Michael Wilschanski; Annie Dupuis; Lynda Ellis; Keith Jarvi; Julian Zielenski; Elizabeth Tullis; Sheelagh Martin; Mary Corey; Lap-Chee Tsui; Peter Durie
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

Review 7.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

Review 8.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

9.  Atypical 5' splice sites cause CFTR exon 9 to be vulnerable to skipping.

Authors:  Timothy W Hefferon; Fiona C Broackes-Carter; Ann Harris; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2002-06-13       Impact factor: 11.025

10.  Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens.

Authors:  Viktoria Havasi; Steven M Rowe; Peter N Kolettis; Didem Dayangac; Ahmet Sahin; Ana Grangeia; Filipa Carvalho; Alberto Barros; Mario Sousa; Lluis Bassas; Teresa Casals; Eric J Sorscher
Journal:  Fertil Steril       Date:  2010-01-25       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.